
For patients with type 2 diabetes taking oral antidiabetics, self-monitoring of blood glucose cost-effectiveness (1 and 3 times per day) was modeled. Both strategies represented good value in the US payer setting.

For patients with type 2 diabetes taking oral antidiabetics, self-monitoring of blood glucose cost-effectiveness (1 and 3 times per day) was modeled. Both strategies represented good value in the US payer setting.
